var data={"title":"Exenatide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Exenatide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/35382?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=exenatide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Exenatide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13796080\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of thyroid C-cell tumors (Bydureon):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exenatide extended release (ER) causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared with controls. It is unknown whether exenatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of exenatide-ER-induced rodent thyroid C-cell tumors has not been determined. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exenatide ER is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of exenatide ER and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with exenatide ER.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595798\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bydureon;</li>\n      <li>Bydureon BCise;</li>\n      <li>Byetta 10 MCG Pen;</li>\n      <li>Byetta 5 MCG Pen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14204425\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bydureon;</li>\n      <li>Byetta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595883\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595906\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2: </b>SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Initial: 5 mcg twice daily within 60 minutes prior to morning and evening meals (or before the two main meals of the day, &ge;6 hours apart); after 1 month, may be increased to 10 mcg twice daily (based on response)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose: </i>If a dose is missed, resume the treatment regimen as prescribed with the next scheduled dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: 2 mg once weekly at any time of day, with or without meals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose:</i> May administer a missed dose as soon as noticed if the next regularly scheduled dose is due in &ge;3 days; resume normal schedule thereafter. If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, do not administer the missed dose and instead resume treatment with the next regularly scheduled dose. To establish a new day of the week administration schedule, wait &ge;3 days after last dose given, then administer next dose on new desired day of the week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Conversion from immediate release to extended release:</i> Initiate weekly administration of exenatide extended release the day after discontinuing exenatide immediate release. <b>Note:</b> May experience increased blood glucose levels for ~2 weeks after conversion. Pretreatment with immediate-release exenatide is not required when initiating extended-release exenatide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595907\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595908\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (CrCl &gt;50 mL/minute): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (CrCl 30 to 50 mL/minute): There are no dosage adjustments provided in the manufacturer's labeling; use caution, particularly with initiation of therapy or dose escalation of immediate release exenatide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (CrCl &lt;30 mL/minute): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD): Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13796181\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, the need for dosage adjustment is unlikely as hepatic dysfunction is not expected to affect exenatide pharmacokinetics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595910\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Auto-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bydureon BCise: 2 mg/0.85 mL (0.85 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bydureon: 2 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Byetta 10 MCG Pen: 10 mcg/0.04 mL (2.4 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Byetta 5 MCG Pen: 5 mcg/0.02 mL (1.2 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted ER, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bydureon: 2 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595803\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119599\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;\">Bydureon: Extended release formulation</p>\n    <p style=\"text-indent:0em;\">Byetta: Immediate release formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50724066\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Bydureon Bcise: FDA approved October 2017; availability anticipated in the first quarter of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10110709\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022200s025lbl.pdf#page=30&amp;token=yZmJx8ooCqF/jMdAfy6Qz7mhqEHWeg/PE127aQeSz4gNCCBhqRmiFKk/DzeOyQ90kkTPvOn+eO15kGPg1Vhh2D9MwNzYZxO54D+ZjmlaFQJStxaF38KeATRYrYZ5Banf&amp;TOPIC_ID=9005\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022200s025lbl.pdf#page=30</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon BCise: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf#page=23&amp;token=Bwa9TmGkMtu2QgJElLeOsDa0HaxspiTzHUmEtXQAF4n9WI27XAHIaExDWfbxZt9IOsdCKbRZdnw66JsvKkibLp3Nlo9FcKMCSZzfuhFPkAHvKMDcNzW2b1eNc/GLRp+B&amp;TOPIC_ID=9005\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf#page=23</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Byetta: <a target=\"_blank\" href=\"https://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf&amp;token=8RYIFfyLhIBYEqeX7m6uPPQEVrZ0DF7DWCCLO7W6cf/u+QyenzwH5zvFYxYJGEes6If3UhK+j6o+jZkDmMe51Q==&amp;TOPIC_ID=9005\" target=\"_blank\">https://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595800\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer via SubQ injection in the upper arm, thigh, or abdomen; rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Use only if clear, colorless, and free of particulate matter. Administer within 60 minutes prior to morning and evening meal (or prior to the 2 main meals of the day, approximately &ge;6 hours apart). Set up each new pen before the first use by priming it. See pen user manual for further details. Dial the dose into the dose window before each administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: May administer without regard to meals or time of day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon single-dose tray: Administer immediately after reconstitution in diluent, the mixture should be white to off-white and cloudy. Do not substitute needles or any other components provided with the single-dose tray.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon Pen: Allow pen to come to room temperature (wait at least 15 minutes after removal from refrigerator) prior to administration. Hold pen by the end with the orange label and tap firmly against palm of hand to mix (may need to tap up to 80 times or more to thoroughly mix); suspension should appear opaque and white to off-white and evenly mixed. Administer immediately after mixing. To ensure full dose is delivered, after insertion of needle press injection button until it clicks and hold for 10 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon BCise autoinjector: Allow autoinjector to come to room temperature (wait at least 15 minutes after removal from refrigerator) prior to administration. Shake autoinjector vigorously for at least 15 seconds; suspension should appear opaque and white to off-white and evenly mixed. Administer immediately after mixing. To ensure full dose is delivered, press autoinjector against skin until it clicks and hold for 15 seconds.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595819\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2:</b> Treatment of type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595844\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence rates are for the extended release formulation unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (extended release: 8% to 11%; immediate release: 8%), diarrhea (extended release: 4% to 11%; immediate release: &ge;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Immunogenicity (20%, injection site reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (17%), injection site nodule (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4% to 8%), dizziness (extended release: 3%; immediate release: &ge;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Injection site pruritus (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (4% to 5%), severe hypoglycemia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (2% to 9%), dyspepsia (extended release: 7%; immediate release: 3%), vomiting (immediate release: 4%, extended release: 3%), decreased appetite (immediate release: &ge;1% to &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (extended release: 6%; immediate release: 1%; associated with glycemic response)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Cardiovascular: Increased heart rate (Robinson 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (all formulations): Abdominal distention, abdominal pain, abscess at injection site, acute pancreatitis, acute renal failure, alopecia, anaphylaxis, angioedema, cellulitis at injection site, drowsiness, dysgeusia, eructation, exacerbation of renal failure, flatulence, hemorrhagic pancreatitis, hypersensitivity reaction, increased serum creatinine, kidney transplant dysfunction, macular eruption, necrotizing pancreatitis, papular rash, prolongation P-R Interval on ECG (Linnebjerg 2011), pruritus, renal function abnormality, renal insufficiency, tissue necrosis at injection site, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595820\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior serious hypersensitivity to exenatide or any component of the formulation; history of or family history of medullary thyroid carcinoma (exenatide ER only); patients with multiple endocrine neoplasia syndrome type 2 (exenatide ER only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bydureon: End-stage renal disease (ESRD) or severe renal impairment (CrCl &lt;30 mL/minute) including dialysis patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Byetta: Diabetic ketoacidosis, diabetic coma/precoma or type 1 diabetes mellitus; end-stage renal disease (ESRD) or severe renal impairment (CrCl &lt;30 mL/minute) including dialysis patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595841\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anti-exenatide antibodies: Use may be associated with the development of anti-exenatide antibodies. Low titers are not associated with a loss of efficacy; however, high titers (observed in 6% to 12% of patients in clinical studies) may result in an attenuation of response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported; discontinue therapy in the event of a hypersensitivity reaction. Serious injection-site reactions (eg, abscess, cellulitis, necrosis), with or without subcutaneous nodules have been reported with use. Isolated cases required surgical intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gallbladder disease: Use of GLP-1 agonists may increase risk of gallbladder and bile duct disease (Faillie 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI symptoms: Most common reactions are GI related; these symptoms may be dose-related and may decrease in frequency/severity with gradual titration and continued use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported; monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain that may radiate to the back, and that may or may not be accompanied by vomiting). Prior to initiating therapy, consider other factors associated with pancreatitis that may be present (eg, hypertriglyceridemia, ethanol abuse, cholelithiasis); it is unknown if exenatide increases the risk for pancreatitis in these patients. If pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Consider alternative antidiabetic therapy in patients with a history of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid tumors: <b>Bydureon: [US Boxed Warning] Thyroid C-cell tumors have developed in animal studies with exenatide ER; it is not known if exenatide ER causes thyroid C-cell tumor, including medullary thyroid carcinoma (MTC) in humans. Patients should be counseled on the potential risk of MTC with the use of exenatide and informed of symptoms of thyroid tumors (eg, neck mass, dysphagia, dyspnea, persistent hoarseness). Use of exenatide ER is contraindicated in patients with a personal or a family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2).</b> Consultation with an endocrinologist is recommended in patients who develop elevated calcitonin concentrations or have thyroid nodules detected during imaging studies or physical exam; routine monitoring of serum calcitonin or using thyroid ultrasound for early detection of MTC is of unknown value. Cases of MTC in humans have been reported with the GLP-1 agonist, liraglutide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Not recommended to be used in patients with gastroparesis or severe GI disease due to frequent GI adverse effects associated with use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use not recommended in severe renal impairment (CrCl &lt;30 mL/minute) or end-stage renal disease (ESRD). Patients with ESRD receiving dialysis may be more susceptible to GI effects (eg, nausea, vomiting), which may result in hypovolemia and further reductions in renal function. Use with caution in patients with renal transplantation or in patients with moderate renal impairment (CrCl 30 to 50 mL/minute), particularly when initiating or escalating doses with immediate-release exenatide. Cases of acute renal failure and chronic renal failure exacerbation, including severe cases requiring hemodialysis, have been reported, predominately in patients with nausea/vomiting/diarrhea or dehydration; renal dysfunction was usually reversible with appropriate corrective measures, including discontinuation of exenatide. Risk may be increased in patients receiving concomitant medications affecting renal function and/or hydration status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection-site reactions: Bydureon: Serious injection-site reactions (eg, abscess, cellulitis, necrosis), with or without subcutaneous nodules, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple dose injection pens: According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duplicate therapy: Avoid concurrent use of extended-release (weekly) and immediate-release (daily) exenatide formulations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299306\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595848\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9005&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Exenatide may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Administer oral contraceptives at least one hour prior to exenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Oral Contraceptive): Exenatide may decrease the serum concentration of Progestins (Oral Contraceptive).  Management: Administer oral contraceptives at least one hour prior to exenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Exenatide may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595804\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595805\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Based on in vitro data, exenatide has a low potential to cross the placenta (Hiles 2003).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013). Agents other than exenatide are currently recommended to treat diabetes in pregnant women (ADA 2018c).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6207220\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if exenatide is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595904\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum glucose, hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]), renal function, weight, triglycerides, signs/symptoms of pancreatitis, signs/symptoms of gallbladder disease (Faillie 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9631065\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595853\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exenatide is an analog of the hormone incretin (glucagon-like peptide 1 or GLP-1) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Exenatide administration results in decreases in hemoglobin A<sub>1c</sub> by approximately 0.5% to 1% (immediate release) or 1.5% to 1.9% (extended release).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595855\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 28.3 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimal systemic metabolism; proteolytic degradation may occur following glomerular filtration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (daily) formulation: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (weekly) formulation: ~2 weeks</p>\n    <p style=\"text-indent:0em;\">Time to peak, plasma: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (daily) formulation: 2.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (weekly) formulation: Single dose: Initial period of release of surface-bound exenatide is followed by a gradual release from microspheres with peaks at week 2 and week 6 to 7 respectively; with once-weekly dosing steady state is achieved at 6 to 7 weeks (Bydureon) and 10 weeks (Bydureon BCise).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (majority of dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422177\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Auto-injector</b> (Bydureon BCise Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/0.85ML (0.85 mL): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pen-injector</b> (Bydureon Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Byetta 10 MCG Pen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/0.04 mL (2.4 mL): $850.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Byetta 5 MCG Pen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/0.02 mL (1.2 mL): $850.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Reconstituted ER</b> (Bydureon Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $198.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038860\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Baietta (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Bayeta (UA);</li>\n      <li>Bydureon (AE, AT, AU, CH, CR, CZ, DE, DK, DO, ES, GB, GT, HK, HN, IE, IL, JP, KR, LT, LU, LV, MT, NI, NL, NO, PA, PL, SE, SG, SI, SK, SV);</li>\n      <li>Byetta (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CY, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG)Committee on Practice Bulletins&mdash;Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/29370047/pubmed\" target=\"_blank\" id=\"29370047\">29370047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blevins T, Pullman J, Malloy J, et al, &quot;DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared With Exenatide Twice Daily in Patients With Type 2 Diabetes,&quot; <i>J Clin Endocrinol Metab</i>, 2011, 96(5):1301-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/ 21307137/pubmed\" target=\"_blank\" id=\" 21307137\"> 21307137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bydureon (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bydureon (exenatide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bydureon BCise (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byetta (exenatide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. <i>JAMA Intern Med</i>. 2016;176(10):1474-1481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/27478902/pubmed\" target=\"_blank\" id=\"27478902\">27478902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiles RA, Bawdon RE, and Petrella EM, &quot;<i>Ex vivo</i> Human Placental Transfer of the Peptides Pramlintide and Exenatide (Synthetic Exendin-4),&quot; <i>Hum Exp Toxicol</i>, 2003, 22(12):623-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/14992323/pubmed\" target=\"_blank\" id=\"14992323\">14992323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linnebjerg H, Seger M, Kothare PA, et al, &ldquo;A thorough QT study to evaluate the effects of single-dose exenatide 10 &micro;g on cardiac repolarization in healthy subjects,&rdquo; <i>Int J Clin Pharmacol Ther</i>. 2011 Oct;49(10):594-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/21961484/pubmed\" target=\"_blank\" id=\"21961484\">21961484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson LE, Holt TA, Rees K, et al, &ldquo;Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis,&rdquo; BMJ Open. 2013 Jan 24;3(1). pii: e001986. doi: 10.1136/bmjopen-2012-001986.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/exenatide-drug-information/abstract-text/23355666/pubmed\" target=\"_blank\" id=\"23355666\">23355666</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9005 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13796080\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F595798\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14204425\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F595883\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F595906\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F595907\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F595908\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13796181\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F595910\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F595803\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28119599\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50724066\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10110709\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F595800\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F595819\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F595844\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F595820\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F595841\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299306\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F595848\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F595804\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F595805\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6207220\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F595904\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F9631065\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F595853\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F595855\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422177\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038860\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9005|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=exenatide-patient-drug-information\" class=\"drug drug_patient\">Exenatide: Patient drug information</a></li></ul></div></div>","javascript":null}